simple antibodytm platform generates - informa connect€¦ · acute myeloid leukemia 2h18: phase 2...
Post on 22-Jun-2020
0 Views
Preview:
TRANSCRIPT
SIMPLE AntibodyTM platform generates unique species cross-reactive antibodies against immune checkpoints
$
Antibody Engineering & Therapeutics Conference
15 December 2017
Erik Hofman, Senior Scientist
Forward Looking Statements
THIS PRESENTATION HAS BEEN PREPARED BY ARGENX SE (“ARGENX” OR THE “COMPANY”) FOR INFORMATIONAL PURPOSES ONLY AND NOT FOR ANY OTHER PURPOSE. NOTHING CONTAINED IN THIS PRESENTATION IS, OR SHOULD BE CONSTRUED AS, A RECOMMENDATION, PROMISE OR REPRESENTATION BY THE PRESENTER OR THE COMPANY OR ANY DIRECTOR, EMPLOYEE, AGENT, OR ADVISER OF THE COMPANY. THIS PRESENTATION DOES NOT PURPORT TO BE ALL-INCLUSIVE OR TO CONTAIN ALL OF THE INFORMATION YOU MAY DESIRE. THIS PRESENTATION ALSO CONTAINS ESTIMATES AND OTHER STATISTICAL DATA MADE BY INDEPENDENT PARTIES AND BY US RELATING TO MARKET SIZE AND GROWTH AND OTHER DATA ABOUT OUR INDUSTRY. THIS DATA INVOLVES A NUMBER OF ASSUMPTIONS AND LIMITATIONS, AND YOU ARE CAUTIONED NOT TO GIVE UNDUE WEIGHT TO SUCH ESTIMATES.
Safe Harbor: Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include those regarding our investigational product candidates and preclinical and clinical trials and the status and related results thereto, future results of operations and financial positions, business strategy, plans and our objectives for future operations. When used in this presentation, the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “will,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions identify forward-looking statements. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company’s control. Such risks include, but are not limited to: the impact of general economic conditions, general conditions in the biopharmaceutical industries, changes in the global and regional regulatory environments in the jurisdictions in which the Company does or plans to do business, market volatility, fluctuations in costs and changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company’s current analysis and expectations include:
failure to demonstrate the safety, tolerability and efficacy of our product candidates; final and quality controlled verification of data and the related analyses; the expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration and European Medicines Agency; the possibility of having to conduct additional clinical trials and our reliance on third parties such as our licensors and collaboration partners regarding our suite of technologies and product candidates. Further, even if regulatory approval is obtained, biopharmaceutical products are generally subject to stringent on-going governmental regulation, challenges in gaining market acceptance and competition. These statements are also subject to a number of material risks and uncertainties that are described in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including in the final prospectus related to the Company’s initial U.S. public offering filed with the SEC pursuant to Rule 424(b) of the Securities Act of 1933, as amended, as well as subsequent filings and reports filed by the Company with the SEC. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.
• Company overview
• SIMPLE antibodyTM platform
• PD-1
• VISTA
• LAG-3
• Innovative access program
Agenda
Validating selective partnerships
Powerful technology suite
Novel concept in autoimmunity
• ARGX-110: first-in-class CD70 antagonist in Phase 1/2 in CTCL and AML
• 4 clinical stage programs; 3 preclinical programs; Innovative Access Program
Deep pipeline with multiple shots on goal
• ARGX-113: first-in-class FcRn antagonist targeting array of IgG mediated AI diseases
• Phase 1: favorable safety profile; IgG reduction up to 85%
• Phase 2: ongoing in myasthenia gravis, immune thrombocytopenia and pemphigus vulgaris
• Strong cash position: €162mm Sept 30, 2017
• Blue chip investor base: more than 50% U.S. Shareholders
• 26.9 mio shares outstanding
• SIMPLE Antibody™: Human V-regions sourced from llama unlock novel & complex targets
• NHance®, ABDEG™, POTELLIGENT®: Fc engineering to augment natural properties of antibodies
• : ARGX-115 (Immuno-oncology-focused novel target GARP)
• $40mm upfront and up to $625mm in potential milestone payments
• Additional partnerships designed to maximize value of platform in non-core areas
Company HighlightsDifferentiated therapeutic antibodies pioneering in severe autoimmune diseases & cancer
Well financed to execute plan
$
4
Discovery
Disciplined Business ModelMaximizes value of our suite of technologies and capabilities
Differentiated mAbsNovel Targetsargenx
Technology Suite
Generating differentiated antibody candidates...
...capturing value at optimal stages
Platform dealsProduct deals
large indications
ARGX-109
ARGX-112
ARGX-116
Bird Rock Bio✓
✓
✓
✓
✓
ARGX-113
ARGX-110
ARGX-115
ARGX-111
✓
Product dealsoutside strategic focus
Product portfolioprogress to clinical PoC
Value inflection point
5
Preclinical development Early & late clinical development
✓
• We obtained the exclusive license option from Broteio Pharma for an antibody against a novel complement target
• We have an antibody discovery alliance with focused on multiple rare disease targets
Deep Pipeline In Severe Autoimmune Diseases and Cancer
6
Product Candidate
Target Indication Preclinical Phase 1 Phase 2 Phase 3 Next Milestone / Commentary
Wholly-Owned Product Candidates
ARGX-113(efgartigimod)
FcRn
Myasthenia Gravis
Immune Thrombocytopenia
Pemphigus Vulgaris
Chronic Autoimmune Diseases
1Q18: Phase 2 topline results
2H18: Phase 2 topline results
2H18: Phase 2 interim data
2H17: Initiate Phase 1 clinical trial
ARGX-110(cusatuzumab)
CD70T-Cell Lymphoma
Acute Myeloid Leukemia
2H18: Phase 2 topline results CTCL
YE17: Interim update Phase 2 CTCL and Phase 1 dose-escalation in AML/MDS
ARGX-111 c-MET Solid Tumors / Blood Cancer Intend to partner
Partnered Product Candidates
ARGX-109(gerilimzumab)
IL-6 Rheumatoid ArthritisEligible for up to €32.5mm in milestones, royalties & additional shares of Bird Rock stock
ARGX-112 IL-22R Skin InflammationEligible for up to ~€100mm in milestones and tiered royalties
ARGX-115 GARP Cancer ImmunotherapyReceived $50mm so far; eligible for up to $625mm milestones & tiered royalties
ARGX-116 ApoC3 DyslipidemiaEligible for double-digit royalties and exclusive option to license the program
Phase 1/2
Phase 1/2
SubQ Formulation
Agenda
• Company overview
• SIMPLE antibodyTM platform
• PD-1
• VISTA
• LAG-3
• Innovative access program
Augmenting Intrinsic Therapeutic Properties Of Antibodies
8
• Llama immune system delivers V-regions with high human homology
V-region
Fc region
SIMPLE Antibody™ Platform
Suite of technologiesTechnology RoleAntibody
Unlock novel and complex targets
We apply our unique suite of technologies to create differentiated product candidates against novel targets
Klarenbeek et al. 2015, mAbsBasilico et al. 2014, J Clin Inv.
Augmenting Intrinsic Therapeutic Properties Of Antibodies
9
• Llama immune system delivers V-regions with high human homology
• Low sequence identity to target protein gives solid immune responses after immunization
• Highly diverse antibody output covers a multitude of target epitopes
V-region
Fc region
SIMPLE Antibody™ Platform
Suite of technologiesTechnology RoleAntibody
Unlock novel and complex targets
We apply our unique suite of technologies to create differentiated product candidates against novel targets
Klarenbeek et al. 2015, mAbsBasilico et al. 2014, J Clin Inv.
Augmenting Intrinsic Therapeutic Properties Of Antibodies
10
• Extends half-life
• Enhances tissue penetration
• Clears disease target
• Clears autoantibodies
• Boosts cell killing
• Llama immune system delivers V-regions with high human homology
• Low sequence identity to target protein gives solid immune responses after immunization
• Highly diverse antibody output covers a multitude of target epitopes
V-region
Fc region
SIMPLE Antibody™ Platform
Suite of technologiesTechnology Role
NHance®
ABDEG™
POTELLIGENT®
Antibody
Unlock novel and complex targets
Modulate immune response
We apply our unique suite of technologies to create differentiated product candidates against novel targets
Klarenbeek et al. 2015, mAbsBasilico et al. 2014, J Clin Inv.
SIMPLE AntibodyTM platform: powerful engine behind argenx’ pipeline
11
SIMPLE AntibodyTM platform: powerful engine behind argenx’ pipeline
12
Agenda
• Company overview
• SIMPLE antibodyTM platform
• PD-1
• VISTA
• LAG-3
• Innovative access program
PD-1: highly successful I/O target
Identity human vs mouse: 61% in extracellular domain
• Multiple functional epitopes: nivolumabversus pembrolizumab
• None of the commercialized anti-PD-1 programs are human/mouse cross-reactive; a surrogate anti-mouse PD-1 antibody was needed
• RMPI-14 is most commonly used surrogate anti-PD-1 antibody for mouse syngeneic tumor models
Tan et al. 2017, .Nat Commun.
Generation human – mouse cross-reactive anti-PD-1 mAbs:• Immunization llama with recombinant human PD-1 protein • Phage selection on recombinant murine PD-1
0 1 0 2 0 3 0
0
1 0 0 0
2 0 0 0
3 0 0 0
D a y s P o s t In je c tio n
tum
ou
r v
olu
me
(m
m³) Is o ty p e
R M P I-1 4 Ig G 2 a
R M P I-1 4 Ig G 2 a F c s ile n t
M C 3 8 tu m o r g ro w th
Epitope mapping Nivolumab and Pembrolizumab
14
15
Characterization of argenx anti-PD1 antibody 10F4
Binding to PD-1 and competition with PD-L1 as measured in flow cytometry
0
5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
2 0 0 0 0 0
B in d in g o n h /m P D -1 t ra n s fe c te d H E K 2 9 3 E
FA
CS
MF
I
1 6 µ g /m l
4 µ g /m l
1 µ g /m l
0 .2 5 µ g /m l
0 µ g /m l
0
5 0
1 0 0
1 5 0
C o m p e t it io n w ith P D -L 1
% c
om
pe
titi
on
1 6 µ g /m l
4 µ g /m l
1 µ g /m l
0 .2 5 µ g /m l
0 µ g /m l
• Binding to transiently PD-1 transfected HEK293 cells• Competition with PD-L1 protein for binding to transiently PD-1 transfected HEK293 cells
Isotype 10F4
hPD1 mPD1 hPD1 mPD1
Isotype 10F4
hPD1 mPD1 hPD1 mPD1
15
Conclusion• 10F4 binds human and mouse PD-1 • 10F4 blocks binding of PD-L1 to both human and mouse PD-1• The argenx anti-PD-1 mAb 10F4 is a human/mouse cross-reactive neutralizer
Anti-PD-1 antibody 10F4 restores T-cell function in human and mouse mixed lymphocyte reaction (MLR)
16
IFNγ release used as read-out for mixed lymphocyte reaction
Is o typ e c tr l 1 0 F 4
0
2 0 0
4 0 0
6 0 0
M o u s e M L R
A b tre a tm e n t (1 0 µ g /m l)
IFN
(p
g/m
l)
Is o typ e c tr l 1 0 F 4
0
5 0 0
1 0 0 0
1 5 0 0
H u m a n M L R
A b tre a tm e n t (1 0 µ g /m l)
IFN
(p
g/m
l)
Conclusion• Anti-PD-1 mAb 10F4 restores T-cell activation in both human and mouse MLR, suggesting
alleviation of PD-1 mediated inhibition
• APC: moDCs• T-cell: CD4+ T-cells
• APC: BMDCs from Balb/C • T-cell: CD4+ T-cells from C57Bl/6 spleen
17
Dahan et al, 2015
RMP1-14 Fc variants
Efficacy study: MC38 syngeneic tumor modelStrong inhibition of tumor growth with 10F4 treatment
Conclusion• Anti-PD-1 mAb 10F4 and RMPI-14 are equally potent in reducing MC38 tumor growth• Removing effector functions dramatically improves the inhibition of tumor growth, in line with
published data from Dahan et al.
0 1 0 2 0 3 0
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
d a y s a fte r tre a tm e n t o n s e t
tum
ou
r v
olu
me
(m
m³)
Is o ty p e
1 0 F 4 m Ig G 2 a
1 0 F 4 m Ig G 2 a F c s ile n t
M e a n tu m o r v o lu m e M C 3 8 + S E M
* * *R M P I-1 4 F c s ile n t
Dahan et al. 2015, Cancer Cell
C57BL/6 mice with MC38 tumor, dosed 2x per week with 10 mg/kg
17
Iso
typ
e
10F
4 W
T
10F
4 F
cD
0
2 0
4 0
6 0
8 0
%C
D8
+ c
ell
s
C D 8 c e lls
*
Iso
typ
e
10F
4 W
T
10F
4 F
cD
0 .0
0 .1
0 .2
0 .3
0 .4
% G
ra
nz
ym
eB
+C
D8
+
C y to to x ic T ly m p h o c y te s
*
*
Iso
typ
e
10F
4 W
T
10F
4 F
cD
0
2
4
6
P ro life ra t in g C D 8 c e lls
%K
i67
CD
8+
Efficacy study: MoA analysis
Conclusion• Higher % of total intratumoral CD8+ T-cells with effector-dead anti-PD1 mAb 10F4• Increased % of proliferating and cytotoxic CD8+ T-cells with effector-dead anti-PD-1 mAb 10F4• Similar observation by Dahan et al, 2015 Cancer Cell• 10F4 is a novel in vitro and in vivo relevant human/mouse cross-reactive checkpoint inhibitor
Flow cytometry analysis of tumor-infiltrating lymphocytes from MC38 model
Establishment of increased active CD8+ T-cell population in MC38 tumors
18
Agenda
• Company overview
• SIMPLE antibodyTM platform
• PD-1
• VISTA
• LAG-3
• Innovative access program
VISTA: target info
• Related to B7 family, in particular PD-L1
• Alternative names: Dies1, Gi24, C10orf54, PD-1H, B7-H5
• Single IgV domain, small intracellular domain
• Functions as both receptor and ligand?
• Binding partner poorly defined (VSIG8, VSIG3?)
• VISTA suppresses T-cell function
• High VISTA expression in MDSCs and TregsVISTA blockade to restore anti-tumor response
• High VISTA expression in AML cells tumortarget (e.g. ADC molecule)
Identity human vs mouse: 69% in extracellular domain
Structure of human VISTA ECD
20
VISTA expression in myeloid and lymphoid cells
Lines et al. 2014, Cancer Res.
Anti-mVISTA antibody 13F3 is mostly used surrogate antibody for syngeneic tumor models
• CT26 (colon carcinoma) tumor model in BALB/c mice• Treatment every 2-3 days with 300 µg anti-VISTA, anti-PD-L1 or combo
Liu et al. 2015 PNAS
Le Mercier et al. 2014 Cancer Res.
• B16-OVA tumor model in C57BL/6 mice• Treatment every 2 days with 300 µg anti-VISTA 13F3
More IFN-γproducing cells in tumor-draining lymph node
21
• Llama immunization with VISTA protein• Phage display selections on recombinant hVISTA yielded a panel of mAbs• Antibody specificity was tested in ELISA
Identification and characterization of argenx anti-VISTA mAb 11C5
h u m a n V IS T A
0 .0 1 0 .1 1 1 0 1 0 0
0
1
2
3
4
6 C 1 1
6 F 3
6 C 4
6 C 5
7 A 1 2
1 1 C 5
7 H 10
a n ti-m V IS T A
m A b (µ g /m l)
OD
45
0
m o u s e V IS T A
0 .0 0 1 0 .0 1 0 .1 1 1 0
0
1
2
3
4
6 C 1 1
6 F 3
6 C 4
6 C 5
7 A 1 2
1 1 C 5
7 H 10
a n ti-m V IS T A
m A b (µ g /m l)O
D4
50
• One unique antibody (11C5) shows binding to both human and mouse VISTA in ELISA
22
Light chain shuffling of 11C5 greatly improves the human-mouse cross-reactivity
0 .0 0 0 1 0 .0 1 1 1 0 0
0
1
2
3
4
C o n c e n tra tio n (g /m l)
OD
45
0 n
m
1 1 C 5 h V IS T A
2 4 B 1 h V IS T A
1 1 C 5 m V IS T A
2 4 B 1 m V IS T A
R e c o m b in a n t V IS T A b in d in g E L IS A
11C
5
24B
1
11C
5
24B
1
0
2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
8 0 0 0 0
1 0 0 0 0 0
B in d in g to H E K -V IS T A
C o n c e n tra tio n (g /m l)M
FI
(PE
)
h V IS T A m V IS T A
• 11C5 heavy chain re-introduced into parental light chain library• Stringent phage display selections to find improved VH-VL pair
24B1 is one of the light chain variants of 11C5• Binding to human and mouse VISTA tested on recombinant protein and cells
• New light chains were identified with improved affinity to VISTA• Light chain shuffled antibodies display a clear human/mouse cross-reactivity on cells• Binding was confirmed on monocytes
23
Antibody 300µg : 3 injections per week I.P.
D1D0 Tumor growth measured by caliper D27
Tumor: s.c.
Anti-VISTA mAb 24B1 shows anti-tumor activity in B16-OVA model
3x105 B16-OVA in C57BL6/j female
Study design
B 1 6 O V A
0 1 0 2 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
Is o ty p e c o n tro l
a n ti-V IS T A 2 4 B 1
a n ti-P D -1
a n ti-V IS T A + a n ti-P D -1
d a y (s )
tu
mo
r v
olu
me
(m
m3
)
* * * *
p < 0 .0 0 0 1
* *
s u r v iv a l c u r v e
d a y (s )
Pe
rc
en
t s
urv
iva
l
0 2 0 4 0 6 0 8 0
0
5 0
1 0 0 Is o ty p e c o n tro l
a n ti-V IS T A 2 4 B 1
a n ti-P D -1
a n ti-V IS T A + a n ti-P D -1
T re a tm e n t
• Anti-VISTA 24B1 is effective in B16-OVA tumors in combo with anti-PD-124
Individual B16-OVA tumor growth curves
A n ti-V IS T A v s is o ty p e
0 2 0 4 0 6 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
Is o ty p e c o n tro l
a n ti-V IS T A 2 4 B 1
d a y (s )
tum
or v
olu
me
(m
m3
)
A n ti-P D -1 v s is o ty p e
0 2 0 4 0 6 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
Is o ty p e c o n tro l
a n ti-P D -1
d a y (s )
tum
or v
olu
me
(m
m3
)
A n ti-V IS T A v s a n ti-P D -1
0 2 0 4 0 6 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
Is o ty p e c o n tro l
a n ti-V IS T A + a n ti-P D -1
d a y (s )
tum
or v
olu
me
(m
m3
)
• Early immune escape is seen in anti-PD-1 treatment group• No early immune escape seen in combo treatment group
-> anti-VISTA can overcome non-responsiveness to PD-1 treatment
25
Agenda
• Company overview
• SIMPLE antibodyTM platform
• PD-1
• VISTA
• LAG-3
• Innovative access program
LAG-3: panel of cross-reactive binders
Identity human vs mouse: 69% in extracellular domain
1 0 -1 1 0 0 1 0 1 1 0 2 1 0 3 1 0 4 1 0 5
0
1
2
3
4
m L A G -3 b in d in g E L IS A
A n ti-L A G -3 (n g /m l)
OD
45
0
1 0 B 5
1 0G 4
1 0 C 8
1 0 E 1 1
1 0 G 11
1 0 E 9
1 0 C 7
4H 51 0 -1 1 0 0 1 0 1 1 0 2 1 0 3 1 0 4 1 0 5
0
1
2
3
4
h L A G -3 b in d in g E L IS A
A n ti-L A G -3 (n g /m l)
OD
45
0
1 0 B 5
1 0G 4
1 0 C 8
1 0 E 1 1
1 0 G 11
1 0 E 9
1 0 C 7
2 5 F 7
• Llama immunization with human LAG-3-Fc protein• ScFv library format for selections on recombinant LAG-3-Fc• Screening for h/m cross-reactive binding
• We identified a collection of h/m cross-reactive anti-LAG-3 antibodies
27
Blocking LAG-3 function: hitting a functional epitope with potential for improvement
28
0 .0 1 0 .1 1 1 0 1 0 0
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0
5 0 0 0 0
C o n c e n tra tio n a n t i-L A G -3 m A b (u g /m l)
RL
U
2 5 F 7
1 0 B 5
1 0 G 11
1 0 C 7
1 0G 4
4H 5
Epitope B
Epitope C
Epitope A
• One group of cross-reactive LAG-3 blocking antibodies identified• Expected to improve potency further by:
• Chain shuffling (cfr. VISTA)• Reformatting to full IgG
• Antibodies (ScFv-Fc) were tested in cell based LAG-3 blocking assay (Promega)LAG-3 inhibition results in TCR signalling and induced luminescence
• Anti-LAG-3 25F7 (Medarex) was used as positive control
Anti-mouse LAG-3
….and also beyond I/O targets !
29
In h ib it io n o f p ro life ra tio n :h u m a n IL -2 4
1 1 0 1 0 0 1 0 0 0 1 0 0 0 0
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
1 C 1 1
1 C 8
1 C 7
1 D 9
m A b (n g /m l)
OD
45
0 n
m
In h ib it io n o f p ro life ra tio n :m o u s e IL -2 4
1 1 0 1 0 0 1 0 0 0 1 0 0 0 0
0 .0
0 .2
0 .4
0 .6
0 .8
1 C 1 1
1 C 8
1 C 7
1 D 9
m A b (n g /m l)
OD
45
0 n
m
• IL-24 antibody 1C11 cross-reactive to human and mouse IL-24 (69% identity)• Functional test for inhibition of IL-24 –dependent cell proliferation
• Antibody 1C11 is a unique, very potent inhibitor of both human and mouse IL-24 signalling• 1C11 was identified in primary screenings • Room for further improvements using the SIMPLE AntibodyTM platform
W T W T IL 2 2 R -/ - IL 2 2 -/ - IL 2 2 -/ -
0
1 0
2 0
3 0
Ea
r t
hic
kn
es
s (
mm
*1
0-2
)
P P D
m A b is o 1 C 1 1
m ic e
In vivo: inhibition of PPD-induced ear swelling
In vitro: inhibition of IL-24 dependent cell proliferation
Conclusions
Summarizing:
- By using llama as third species we generated panels of human/mouse cross-reactive SIMPLE AntibodiesTM against multiple immune checkpoint targets
- In vitro and/or in vivo studies confirmed unique cross-reactive functionality of these antibodies
- Having human-cyno-mouse cross-reactive antibodies significantly de-risks the therapeutic lead candidate
30
31
Establishing close collaborationswith renowned research groups
Leveraging the power of our unique antibody technology platform
Unlocking novel targets,elucidating target biology
Creating first-in-class antibodieswith therapeutic product potential
Set-up a win-win collaboration: Rapid PoC in disease models; Scientific publications, new IP; Development candidates
Innovative Access Program (IAP): Uniting world-class mAbexpertise with novel targets
WANT TO DISCUSS COLLABORATIONOPPORTUNITIES? CONTACT US.iap@argenx.comwww.argenx.com
Collaboration with UCL/ DeDuve Institute
Patented inventions on GARP & ARGX-115
Pioneering work in immuno-Oncology
Patent published
PoC established, option exercised
Science Translational Medicine publication
AbbVie deal: $40m upfront / early MS
Financial return to UCL/ DeDuve Institute
ARGX-115: IAP success story
32
Establishing close collaborationswith renowned research groups
Leveraging the power of our unique antibody technology platform
Unlocking novel targets,elucidating target biology
Creating first-in-class antibodieswith therapeutic product potential
Set-up a win-win collaboration: Rapid PoC in disease models; Scientific publications, new IP; Development candidates
Innovative Access Program (IAP): Uniting world-class mAbexpertise with novel targets
WANT TO DISCUSS COLLABORATIONOPPORTUNITIES? CONTACT US.iap@argenx.comwww.argenx.com
Many thanks to:
33
argenx BVBABas van der WoningGitte de BoeckLiesbeth HeyndrickxChristel DubuissonKathleen MoensJulie GhyselinckNico OngenaeValérie HanssensChristophe BlanchetotHans de HaardMichael Saunders
FairJourney BiologicsMaria PajueloIldikó TóthDaniela Teixeira Diana RamosJoana Gomes
VIB (Flamish Biotechnology Institute)Eline Haspeslagh
Radboud University NijmegenMichael ValenteCarl Figdor
Crown BioFei ChenQiu Tan
Thank you
WANT TO DISCUSS COLLABORATIONOPPORTUNITIES? CONTACT US.iap@argenx.comwww.argenx.com
top related